Histone Deacetylase Inhibitors Market Players:
- Acrotech Biopharma Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bristol Myers Squibb Co.
- Celleron Therapeutics Ltd.
- Novartis AG
- Midatech Pharma PLC
- REGENACY PHARMACEUTICALS, INC.
- Syndax Pharmaceuticals Inc.
- Viracta Therapeutics Inc.
- Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
- Cetya Therapeutics Inc.
- Italfarmaco SpA
- Vanda Pharmaceuticals Inc.
The market evolving its dynamics with the continuous participation in rigorous R&D cohorts by key players. They are heavily investing in advanced technologies to conduct clinical trials more efficiently and to mitigate related hurdles. Furthermore, the support from regulatory frameworks is escalating the pace of both domestic and international commercialization. For instance, in August 2021, Celgene Corporation attained accelerated approval from the FDA for its histone deacetylase (HDAC) inhibitor, Istodax (romidepsin). This drug is indicated to be used as a monotherapy for treating peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. Such key pioneers are:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of histone deacetylase inhibitors is evaluated at USD 1.53 billion.
The global histone deacetylase inhibitors market size exceeded USD 1.43 billion in 2025 and is set to expand at a CAGR of over 7.6%, surpassing USD 2.97 billion revenue by 2035.
By 2035, North America is predicted to capture a 35.1% share of the histone deacetylase inhibitors market, underpinned by escalating healthcare technology investments and clinical R&D expansion.
Key players in the market include Novartis AG, Midatech Pharma PLC, REGENACY PHARMACEUTICALS, INC., Syndax Pharmaceuticals Inc., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., Cetya Therapeutics Inc., Tokyo Chemical Industry Co. Ltd., AstraZeneca Plc.
